XTalks

JUNE 5, 2023

GLP-1 stimulates insulin production, thus reducing blood glucose levels, and it interacts with the brain to suppress appetite and create a feeling of fullness. Furthermore, patients should only purchase Ozempic, Wegovy or other medications from licensed healthcare providers or pharmacies.

FDA Approval 98

FDA Approval Containment Drugs Pharmacy 98

Roots Analysis

AUGUST 1, 2024

Increasing Preference for Oral Drug Formulations: There has been a shift towards the development of oral forms of GLP-1 drugs (which are generally administered via injections), owing to their several benefits, such as ease of use, flexibility in administering the medication at home and improved patient compliance. per package in the US.

Marketing 52

Marketing Insulin Drugs Development 52

Roots Analysis

FEBRUARY 22, 2022

We observed that many companies have entered this field by in-licensing technologies from other players to establish the necessary expertise required to develop / manufacture autoinjectors. It is important to highlight that 75% of the total deals signed in 2021 ( till August ) are licensing agreements. Concluding Remarks.

Drug Delivery 52

Drug Delivery Production Marketing Development 52

XTalks

JUNE 12, 2023

Internationally, Medtronic expanded its MiniMed 780G insulin pump and Guardian 4 sensor. This acquisition granted BD access to advanced assays licensed from the EuroFlow Consortium, an independent scientific network in hematology and immunology. It also plans to launch these products in the US.

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

FDA Law Blog

DECEMBER 3, 2023

covered insulin product or vaccine). Audits and Compliance Monitoring: Using its discretionary authority under 42 U.S.C. CMS may similarly audit participating manufacturers up to once a year to monitor their compliance after a similar 60-day notice of a reasonable basis for the audit. state pharmaceutical assistance programs).

Manufacturing 105

Manufacturing Drugs Compliance Pharmacy 105

The Pharma Data

AUGUST 3, 2021

The company announced donanemab received Breakthrough Therapy designation for treatment of Alzheimer’s disease and its intention to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. 25% $ 2,988.1 $ 2,459.1 22% Humalog ®(a) 607.6

Antibody 52

Antibody Sales Development Production 52